Viebacher: Drug R&D Future Is In Collaboration, But Safe Harbors Needed
This article was originally published in The Pink Sheet Daily
Sanofi CEO says firms and other healthcare stakeholders all need to work together, but “no good deed goes unpunished.”
You may also be interested in...
More clinical trials move to Denmark, Sanofi’s Viehbacher moves to Boston, and analysts suggest thwarted Pfizer’s next strategic move may be to use contingent value rights in a future attempt for AstraZeneca, plus more in this month’s notebook.
With $230 million from industry and NIH, the Accelerating Medicines Partnership will seek to hasten and improve the success rate for discovery of biomarkers and therapeutic pathways in Alzheimer’s, type 2 diabetes, rheumatoid arthritis and lupus.
Alzheimer’s disease research could be a beneficiary of Europe’s plan to include more non-EU partners in its new science funding program, Horizon 2020, and a new version of its public-private partnership with the pharmaceutical industry, the Innovative Medicines Initiative.